Welcome to our dedicated page for Aytu Biopharma SEC filings (Ticker: AYTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Most Aytu BioPharma investors start with two questions: How quickly is the pediatric ADHD franchise scaling, and what are insiders doing with their shares? Those answers live inside a maze of 10-Ks, 10-Qs, 8-Ks and Form 4s. Our SEC filings hub guides that journey from first click to final model.
Type a natural query—“Aytu BioPharma quarterly earnings report 10-Q filing” or “Aytu BioPharma insider trading Form 4 transactions”—and land on real-time disclosures the moment they hit EDGAR. Stock Titan’s AI instantly produces concise, plain-English summaries, turning dense sections on R&D spend or revenue by therapeutic class into actionable paragraphs. You’ll also find:
- Aytu BioPharma annual report 10-K simplified—cash runway, ADHD sales mix, urology pipeline timelines
- Aytu BioPharma Form 4 insider transactions real-time—executive stock transactions and option exercises
- Aytu BioPharma 8-K material events explained—from trial data releases to licensing agreements
- Aytu BioPharma proxy statement executive compensation—equity incentives and board alignment
Need deeper context? Select “understanding Aytu BioPharma SEC documents with AI” to compare footnote language across quarters or generate ratio tables without touching a spreadsheet. Practical use cases include monitoring Form 4 insider buys ahead of FDA milestones, reviewing segment revenue trends for earnings-report filing analysis, and flagging covenant changes hidden in debt footnotes.
Whether you’re screening small-cap pharma, preparing a due-diligence memo, or tracking Aytu BioPharma executive stock transactions Form 4, our platform surfaces what matters and updates the moment the company files. Complex SEC filings explained simply—so you can act before the market does.
AWM Investment Company, Inc. reports beneficial ownership of 619,874 shares of AYTU BioPharma common stock, equal to 6.9% of the class. These shares are held by Special Situations Private Equity Fund, L.P. (SSPE), for which AWM serves as investment adviser and over which AWM states it has sole voting and sole dispositive power.
The filing identifies David M. Greenhouse and Adam C. Stettner as controlling principals of AWM and members of MG Advisers, L.L.C., the general partner of SSPE. The filer certifies the securities were acquired in the ordinary course of business and are not held to change or influence control of the issuer.
Stonepine Capital and related reporting persons jointly report a 9.9% beneficial interest in AYTU BioPharma. The Schedule 13G discloses an aggregate position of 906,063 shares with shared voting and dispositive power and no sole voting or dispositive power. The reported position is calculated using 8,976,314 shares outstanding as of June 9, 2025.
The filing specifies the composition of the position as 812,676 shares of common stock plus prefunded and tranche warrants (prefunded warrants to acquire 2,446,883 shares; Tranche A and Tranche B warrants to acquire 815,217 shares each), and notes those warrants are subject to a 9.99% beneficial ownership limitation.
Kanen Wealth Management LLC, together with its affiliated funds Philotimo Fund LP and Philotimo Focused Growth & Income Fund, filed a Schedule 13G disclosing an aggregate ownership of 573,358 shares of AYTU BioPharma, Inc. ("AYTU") common stock as of 26 June 2025. This represents 6.4 % of AYTU’s 8,976,914 shares outstanding. Although the stake surpasses the 5 % reporting threshold, the 13G filing indicates the position is presently passive rather than activist in nature.
Stake distribution is as follows:
- Philotimo Fund LP: 384,150 shares (4.3 % of outstanding)
- Philotimo Focused Growth & Income Fund: 189,208 shares (2.1 % of outstanding)
- Kanen Wealth Management LLC / David L. Kanen: deemed beneficial owner of the full 573,358-share group position via control relationships.
The group expressly certifies the holdings were acquired without the intent to change or influence control of AYTU, satisfying the passive-investor criteria under Rule 13d-1. No additional transactions, purchase prices, or financing details were provided. While a 6.4 % passive stake signals meaningful external confidence, it does not by itself alter AYTU’s governance or capital structure.
Amendment No. 2 to Schedule 13G discloses that several related entities – Philotimo Fund LP, Philotimo Focused Growth & Income Fund (a series of World Funds Trust), Kanen Wealth Management LLC, and David L. Kanen – collectively own 166,268 shares of AYTU BioPharma, Inc. common stock.
Based on the issuer’s 6,170,246 shares outstanding as of 1 May 2025, the group’s holding represents approximately 2.7 % of the company’s equity.
Individually, Philotimo Fund holds 111,400 shares (1.8 %), while the Philotimo Focused Growth & Income Fund holds 54,868 shares (0.9 %). Kanen Wealth Management, as general partner and investment manager, and Mr. Kanen, as managing member, are each deemed to beneficially own all 166,268 shares through shared voting and dispositive power. No party reports sole voting or dispositive authority; all authority is shared among the reporting persons.
The filing is made pursuant to Rule 13d-1(c), indicating a passive investment below the 5 % threshold that would require a Schedule 13D. Each reporting person expressly disclaims beneficial ownership of shares not directly held. The event triggering the filing occurred on 22 May 2025, and the ownership percentages rely on share-count data from AYTU’s 14 May 2025 Form 10-Q.
Because the combined stake is below 5 %, the amendment does not signal a change in control or confer significant influence; however, it formally records the aggregated position and clarifies governance relationships among the entities.
Kanen Wealth Management LLC, its managing member David L. Kanen, and two affiliated funds (Philotimo Fund LP and Philotimo Focused Growth & Income Fund) filed an Amendment No. 1 to Schedule 13G reporting their collective ownership of 635,073 shares of AYTU BioPharma, Inc. (“AYTU”) common stock as of 15 May 2025.
The filing shows that the group now beneficially owns approximately 10.3 % of AYTU’s 6,170,246 outstanding shares (per AYTU’s 14 May 2025 Form 10-Q). Ownership is held passively under Rule 13d-1(c):
- Philotimo Fund LP: 425,500 shares (6.9 %)
- Philotimo Focused Growth & Income Fund: 209,573 shares (3.4 %)
- Kanen Wealth Management LLC & David L. Kanen: deemed beneficial owners of the full 635,073 shares (10.3 %) through control of the two funds
The signatories certify the securities were not acquired with the purpose of influencing control of the issuer. All voting and dispositive powers are reported as shared; none of the parties report sole power to vote or dispose of the shares. The principal business address for all reporting persons is 6810 Lyons Technology Circle, Suite 160, Coconut Creek, FL 33073.
The disclosure establishes Kanen Wealth Management and its affiliates as a newly recognized 10 % passive institutional holder of AYTU, a potentially supportive signal for other investors given the stake size and long-only filing status.
On June 20, 2025, Aytu BioPharma, Inc. (AYTU) executed Amendment No. 6 to its Loan and Security Agreement with Eclipse Business Capital. The amendment affects both the company’s term loan and revolving credit facility.
- Maturity extension: The $13.0 million Eclipse Term Loan and the Eclipse Revolving Loan now mature on June 12, 2029, giving AYTU an additional four-year runway.
- Incremental liquidity: A $1.5 million incremental advance was added to the revolving facility, priced at SOFR + 5.50%.
- Amortisation schedule: Repayment of the incremental advance begins August 1, 2025 at $125,000 per month until the advance is fully repaid.
- Borrowing-base flexibility: The amendment increases borrowing-base availability by permitting 25% concentration limits on certain independent pharmacy distributors.
- Regulatory disclosure: The transaction constitutes a direct financial obligation (Item 2.03). A press release dated June 23, 2025 (Exhibit 99.1) publicised the amendment; no earnings or operational updates were included.
The deal strengthens near-term liquidity and extends debt maturities, though at a relatively high floating rate and with scheduled principal reductions that will affect future cash flow.
FAQ
What is the current stock price of Aytu Biopharma (AYTU)?
What is the market cap of Aytu Biopharma (AYTU)?
